SGLT2 inhibitors in cardiac amyloidosis: mechanistic insights and clinical perspectives-a narrative review.

SGLT2i use was associated with significantly fewer HF exacerbations (HR 0.64, 95% CI 0.48–0.86; p < 0.01), all-cause hospitalizations (HR 0.72, 95% CI 0.58–0.91; p < 0.01), and acute kidney injury (HR 0.53, 95% CI 0.35–0.79; p < 0.01), with a nonsignificant trend toward lower all-cause mortality (HR 0.83, 95% CI 0.63–1.08; p = 0.165) [ 45 ].

also in 5,406 other papers

The functional class was largely preserved, showing a trend toward improvement from NYHA III to II, alongside numerical reductions in the hospitalization rate and albuminuria; however, these changes did not reach statistical significance [ 54 ].

also in 111,027 other papers